Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07328948 drug interaction study with cyclosporine and clarithromycin
NCT06837259Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-07328948 (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration of PF-07328948 at 72 hours, Area Under the Curve From Time Zero to Extrapolated Infinite Time of PF-07328948 at 72 hours and 1 more. Started Mar 2025; status: completed.
02
Drugs
PF-07328948
Beyond the preview
Go deeper on NCT06837259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837259.